AJANTPHARM - Swing Trade Analysis with AI Signals

Last Updated Time : 05 Nov 25, 7:43 am

✅ Swing Trade Rating: 4.0

Entry Zone: ₹2,560–₹2,580 (only if RSI cools below 65 and MACD sustains)

Exit if held: ₹2,980–₹3,050 (near resistance and brokerage target zone)

📊 Technical & Fundamental Snapshot

• 📈 Current Price: ₹2,596
• 📈 52W High/Low: ₹3,147 / ₹2,022
• 📈 RSI: 69.2 (approaching overbought)
• 📈 MACD: 7.31 (bullish crossover)
• 📈 Volume: 3.28L vs 1W Avg 1.56L (strong surge)
• 📉 FII Holding Change: -0.33%
• 📈 DII Holding Change: +0.40%
• 📈 P/E: 34.1 vs Industry 33.1 (fair valuation)
• 📉 PEG Ratio: 4.30 (growth priced high)

✅ Positive

• 📈 ROCE & ROE: 33.0% and 25.7% — elite capital efficiency.
• 📉 Low Debt: Debt-to-equity at 0.01 — virtually debt-free.
• 📈 EPS: ₹76.1 — strong earnings base.
• 📈 Volume Spike: Indicates institutional interest and breakout potential.
• 📈 Above DMA 50 & 200: Price trending above key averages.

⚠️ Limitation

• 📉 RSI > 69: Overbought — risk of short-term pullback.
• 📉 FII Exit: Foreign investors trimmed stake.
• 📉 PEG Ratio: 4.30 — growth priced at a premium.

🚨 Company Negative News

• 📉 Flat PAT: ₹250 Cr vs ₹255 Cr QoQ — margin pressure from product mix and opex.
• 📉 Financial Trend Adjustment: MarketsMojo downgraded outlook from positive to flat due to slower PAT growth.

📈 Company Positive News

• 🚀 Q2FY26 PAT: ₹260 Cr — up 20% YoY; revenue ₹1,354 Cr, up 14% YoY.
• 📈 Therapy Leadership: Outperforming in ophthalmology, dermatology, pain, and expanding into gynecology and nephrology.
• 📦 US Generics: Revenue up 48% YoY — strong traction despite sector headwinds.
• 📈 Brokerage Targets: Motilal Oswal: ₹3,000; Nuvama: ₹3,250 — 15–25% upside.

💊 Industry

• 📈 Branded Generics: India and emerging markets showing strong volume growth.
• 📉 US Generic Pressure: Larger players facing margin compression — Ajanta gaining share.

🧾 Conclusion

• ✅ Strong swing setup with volume, MACD, and sector tailwinds.
• 📥 Entry near ₹2,560–₹2,580 if RSI cools below 65 and MACD sustains.
• 📤 Exit near ₹2,980–₹3,050 (resistance and brokerage target zone).
• 📈 Fundamentals robust, momentum strong — suitable for tactical trades with alert logic and basket overlay.

Sources

Motilal Oswal Buy Rating

Nuvama Institutional View

Q2 Results & Dividend

MarketsMojo Trend Adjustment

CNBC TV18 Q2 Summary